Name: Cadrenal Therapeutics, Inc. (CVKD) Financial Statements
Creator: FinSpry

Cadrenal Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Cadrenal Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2024	Dec 2023	Dec 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.22	0.00
Gross Profit	0.00	-0.22	0.00
Operating Expenses
Research & Development	4.21	4.08	0.43
Selling, General & Administrative	6.75	3.55	2.52
Operating Expenses	10.96	7.63	2.95
Operating Income	-10.96	-7.63	-2.95
Other Income/Expense
Interest Income	0.31	0.25	0.00
Interest Expense	0.00	-0.02	-0.12
Other Income/Expense	0.31	-0.22	-4.26
Income
Income Before Tax	-10.65	-8.36	-7.32
Income Tax Expense	0.00	-0.14	0.00
Net Income	-10.65	-8.36	-7.32
Net Income - Continuous Operations	-10.65	-8.36	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00
EBITDA	-10.96	-7.63	-2.95
EBIT	-10.96	-7.63	-2.95
Depreciation & Amortization	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-9.00	-9.00	-14.00
Diluted EPS	-9.00	-9.00	-14.00
Basic Shares Outstanding	1.22	0.90	0.53
Diluted Shares Outstanding	1.22	0.90	0.53